Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

study id #: NCT02420379

condition: Duchenne Muscular Dystrophy (DMD)

status: completed

This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

intervention: eteplirsen

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT02420379

last updated: March 12, 2019

start date: July 1, 2015

estimated completion: December 17, 2018

phase of development: Phase 2

size / enrollment: 33

study description:
Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.
Clinical efficacy, including functional tests and MRI, will be assessed at regularly scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.
Population and serial PK will be collected.

primary outcomes:

• Number of patients with treatment emergent adverse events [Time Frame: 96 weeks]

secondary outcomes:

• Change from baseline in percent of dystrophin-positive skeletal muscle fibers [Time Frame: 96 weeks]

inclusion criteria:
• Male 4-6 years of age.
• Diagnosis of DMD, genotypically confirmed.
• Stable dose of oral corticosteroids for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
• Intact right and left biceps muscles or two alternative upper arm muscle groups.
• Parent that is willing to provide consent and comply with study procedures.

exclusion criteria:
• Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
• Previous or current treatment with any other experimental treatments within 12 weeks or participation in any other clinical trial within 6 months.
• Major surgery within 3 months prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study activities.
• Presence of other clinically significant illness.

sponsor: Sarepta Therapeutics

investigators: Medical Director; Sarepta Therapeutics, Inc.

locations: United States